Weissert 1 Cost-Benefit, Cost-Effectiveness Analysis, and An Application to Home Care William Weissert Professor and Chair Department of Health Management.

Slides:



Advertisements
Similar presentations
Making Payment Reforms Work for Patients and Families Lee Partridge Senior Health Policy Advisor National Partnership for Women and Families January 28,
Advertisements

PAYING FOR PERFORMANCE In PUBLIC HEALTH: Opportunities and Obstacles Glen P. Mays, Ph.D., M.P.H. Department of Health Policy and Administration UAMS College.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlikeLicense. Your use of this material constitutes acceptance of that license.
ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
John Amson Capitman, PhD. Nickerson Professor of Health Policy Central Valley Health Policy Institute California State University, Fresno.
Health Outcomes Research and Policy Center Joseph Thomas III, M.S., Ph.D., FAPhA.
Capital Budgeting Processes And Techniques
INVESTMENT APPRAISAL NON DISCOUNTING By Lucky Yona.
We show that MP can be used to allocate resources to treatments within and between patient populations, using a policy-relevant example. The outcome is.
Economic Analysis and Management Todd Wagner, PhD.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
1 Value of Life Analysis Scott Matthews Courses: / /
Long-Term Care in a Global Context. Demographics Population aging globally Increased numbers of older adults (esp. oldest- old) means increased need for.
The Future of Health Care for Older People: Will the Disadvantaged by Left Behind? Chad Boult, MD, MPH, MBA Professor and Director Lipitz Center for Integrated.
317_L25, Mar J. Schaafsma 1 Review of the Last Lecture Have discussed three methods for shadow pricing life and limb for CBA: human capital method,
Budget and Finance Concepts for the CNL Susan J. Penner, RN, MN, MPA, DrPH, CNL.
1 Civil Systems Planning Benefit/Cost Analysis Scott Matthews Courses: and Lecture /6/2002.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Chapter 11: Cost-Benefit Analysis Econ 330: Public Finance Dr
Integration, cooperation and partnerships
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Basic Tools of Finance Finance is the field that studies how people make decisions regarding the allocation of resources over time and the handling of.
The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.
Elderly Housing. Types of Housing  Assisted Living : Also called residential care, is a type of living arrangement in which personal care services such.
Comments on Rudolph G. Penner and Richard W. Johnson, “Health Care Costs, Taxes, and the Retirement Decision” Alan Gustman August 10, 2006.
Public Policy Analysis MPA 404 Lecture 21. Previous Lecture Distribution of resources as a rationale for policy interventions The Social Welfare Function.
Pathway Model: A Tool to Measure Outcomes Target Population Engage those at greatest risk Assure connection to evidence-based intervention Measureable.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Presentation to Inclusion Ireland Conference & AGM Pat Healy – National Director Social Care 10 th May, 2014.
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
Addressing The Boom Trends in Aging and Long-Term Care Florida Conference on AgingAugust 31, 2004.
Stephanie Hull MGA Conference Chief, Long Term Services and Supports June 7, 2012 Maryland Department of Aging.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
What cost evidence supports the use of technologies in home and community based caregiving of older adults? Presented by Brooke Harrow, PhD University.
Normative Criteria for Decision Making Applying the Concepts
Value Based Insurance Design Michael Chernew Oct 10, 2008 Portions of this research were funded by Pfizer and GSK.
WE’VE COME A LONG WAY … Deaths due to heart attack cut in half Days spent in hospitals cut by 56% Increased life expectancy by 3.2 years ADVANCES IN.
Phaedra Corso, Ph.D. Associate Professor College of Public Health University of Georgia Program Evaluation from an Economic Perspective.
Targeted Interventions in Health Care: The case of PROMIN Sebastian Galiani Mercedes Fernandez Ernesto Schargrodsky.
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
How Much Would A Medicare Prescription Drug Benefit Cost? Offsets in Medicare Part A Cost by Increased Drug Use Zhou Yang, Ph.D. Assistant Professor Department.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Healthy Alaska Plan Alaska Medicaid Redesign Initiative North Star Council on Aging Senior Center presented by Denise.
1 Greater Manchester Public Service Reform and Early Years March 2014.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
Copyright © 2009 Pearson Addison-Wesley. All rights reserved. Chapter 3 Valuing the Environment: Methods.
Managed long-term care: Perspectives from a Managed Care Organization October 24, 2011 Managed Long-Term Care:
Managing Public Budget to Facilitate Economic Growth and Reduce Poverty Public Expenditure Analysis & Management Staff Training Course May , 2001.
Africa Impact Evaluation Program on AIDS (AIM-AIDS) Cape Town, South Africa March 8 – 13, Steps in Implementing an Impact Evaluation Nandini Krishnan.
The financial costs and benefits of alcohol The financial costs and benefits of alcohol Christine Godfrey Department of Health Sciences & Centre for Health.
Flagship Program on Health Sector Reform and Sustainable Financing.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Health Policy Analysis: Chapters 10, 11 and 14 Nutchanart Bunthumporn Beth Faiman.
McGraw-Hill/Irwin Copyright © 2004 by the McGraw-Hill Companies, Inc. All rights reserved. Chapter 2 Objective and Risk Management.
Cost and Benefits. Introduction Is treatment X worth it?
EVALUATION RESEARCH To know if Social programs, training programs, medical treatments, or other interventions work, we have to evaluate the outcomes systematically.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Long Term Care The Continuum of Care. What is Long Term Care? Health, mental health, social and residential services provided to temporarily or chronically.
CRJS 4466 PROGRAM & POLICY EVALUATION LECTURE #6 Evaluation projects Questions?
THE ROLE OF INTERMEDIATE CARE IN DELIVERING IMPROVED OUTCOMES FOR OLDER PEOPLE Seminar Presentation November 2015 By Professor John Bolton (Institute of.
Impact and outcomes – making sure these are central to your case –
Presentation transcript:

Weissert 1 Cost-Benefit, Cost-Effectiveness Analysis, and An Application to Home Care William Weissert Professor and Chair Department of Health Management and Policy, School of Public Health University of Michigan Ann Arbor

Weissert 2 Outline Key concepts and examples –Types of cost-analysis An application of cost-benefit analysis to home care budgeting Take away points on Cost Effectiveness Analysis (CEA)

Weissert 3 Cost-Benefit Ratio $Cost Intervention - $Cost Comparison $Benefits Intervention - $Benefits Comparison

Weissert 4 Compared to What? What’s the intervention? Expanded home care benefits What’s the comparison group? Usual care –What they’re already getting: not nothing What’s the marginal cost? How much additional spending is made What’s the marginal benefit? What are the additional benefits –Over what they would have been without the intervention?

Weissert COST EFFECTIVENESS ADOPTCEA REJECT ADOPT? REJECT? ADOPT? REJECT? Source: Cliff Goodman, Lewin Assoc.

Weissert 6 Whose Costs, Who’s Benefits Patient Family Provider Medicaid Medicare or other payer Society at large

Weissert 7 Types of Economic Analysis Cost - Minimization: $ vs. $ (same outcome) Cost - Effectiveness: $/ Outcome units Cost - Utility: $/Quality units Cost - Benefit: $/$ or ($-$)

Weissert 8 Cost-Minimization Analysis (Hospvisits 2 *Hospcosts 2 )+(ERvisits 2 *ER$ 2 )+(OPvisits 2 *OP$ 2 )+ (HCvisits 2 *HC$ 2 )+(Trans 2 *Trans$ 2 )+(Nhadmits 2 *NHdays 2 *NH $/day 2 )+(Infhrs 2 *Inf$ 2 )+(DMEunits 2 *DME$ 2 )+(Prescribe 2 *Pres cribe$ 2 )+(Disposunits 2 *Disposunits$ 2 )+(Housingdays 2 *Housing $ 2 )+(Meals 2 *Meals$ 2 )+or(Copay 2 *Copay$ 2 ) + (NewTreat 2 *NewTreat$ 2 ) minus (Hospvisits 1 *Hospcosts 1 )+(ERvisits 1 *ER$ 1 )+(OPvisits 1 *OP$ 1 )+ (HCvisits 1 *HC$ 1 )+(Trans 1 *Trans$ 1 )+(Nhadmits 1 *NHdays 1 *NH $ 1) +(Infhrs 1 *Inf$ 1 )+(DMEunits 1 *DME$ 1 )+(Prescribe 1 *Prescribe $ 1 )+(Disposunits 1 *Dispos$ 1 )+(Housingdays 1 *Housing$ 1 )+(Mea ls 1 *Meals$ 1 )+or-(Copay 1 *Copay$ 1 ) equals Net cost difference (+ or -)

Cost-Minimization Example Weissert 10

Weissert 10 Cost-Effectiveness Analysis [(Hospvisits 2 *Hospcosts 2 )+(ERvisits 2 *ER$ 2 )+(OPvisits 2 *OP$ 2 )+(HCv isits 2 *HC$ 2 )+(Trans 2 *Trans$ 2 )+(Nhadmits 2 *NHdays 2 *NH$ 2) +(Infhrs 2 *Inf$ 2 )+(DMEunits 2 *DME$ 2 )+(Prescribe 2 *Prescribe$ 2 )+(Disposunits 2 *Dispos$ 2 )+(Housingdays 2 *Housing$ 2 )+(Meals 2 *Meals$ 2 )+or- (Copay 2 *Copay$ 2 ) +(NewTreat2*NewTreat$2)] minus [(Hospvisits 1 *Hospcosts 1 )+(ERvisits 1 *ER$ 1 )+(OPvisits 1 *OP$ 1 )+(HCv isits 1 *HC$ 1 )+(Trans 1 *Trans$ 1 )+(Nhadmits 1 *NHdays 1 *NH$ 1 )+(Infhrs 1 *Inf$ 1 )+(DMEunits 1 *DME$ 1 )+(Prescribe 1 *Prescribe$ 1 )+(Disposunits 1 *Dispos$ 1 )+(Housingdays 1 *Housing$ 1 )+(Meals 1 *Meals$ 1 )+or- (Copay 1 *Copay$ 1 )] divided by [Units of a Single Outcome 2 (such as %Satisfied or Days in Community) minus Units of the same Single Outcome 1 ] equals Net cost per increased unit of Same Single Outcome (+ or -)

Cost-Effectiveness Example Weissert12

Weissert 12 Measuring Utiles Utiles are usually measured in QALYs QALYs are Quality Adjusted Life Years – (1 year of life at full health minus adjusted for reduced quality) –e.g., if one year of full health equals 1 QALY –and having one ADL dependency reduces the value of life by 20% –then prevention of loss of independence in one ADL=.2QALY %reduction is arbitrary, or preference based –I used, 5ADL dependency=0 Quality of Life (0 QUALYs) May understate value of 5ADL dependent life - and thus overstates value of preventing a single ADL decline

Weissert 13 Cost-Benefit Analysis [(Hospvisits 2 *Hospcosts 2 )+(ERvisits 2 *ER$ 2 )+(OPvisits 2 *OP$ 2 )+(NHadmits 2 *NHdays 2 *NH$ 2 )+(Trans 2 *Trans$ 2 )+(Infhrs 2 *Inf$ 2 )+(DMEunits 2 *DME$ 2 )+( Prescribe 2 *Prescribe$ 2 )+(Disposunits 2 *Dispos$ 2 )+(Housingdays 2 *Housing$ 2 ) +(Meals 2 *Meals$ 2 )+or-(Copay 2 *Copay$ 2 ) +(NewTreat 2 *NewTreat$ 2 ) minus (Hospvisits 1 *Hospcosts 1 )+(ERvisits 1 *ER$ 1 )+(OPvisits 1 *OP$ 1 )+(NHadmits 1 * NHdays 1 *NH$ 1 )+(Trans 2 *Trans$ 1 )+(Infhrs 1 *Inf$ 1 )+(DMEunits 1 *DME$ 1 )+(P rescribe 1 *Prescribe$ 1 )+(Disposunits 1 *Dispos$ 1 )+(Housingdays 1 *Housing$ 1 )+ (Meals 1 *Meals$ 1 )+or-(Copay 1 *Copay$ 1 )] divided by [(Units of outcomeA 2 *$value per unit of outcomeA 2 )+(Units of outcomeB 2 *$value of outcomeB 2 )+ (Units of outcomeN 2 *$value per unit of outcomeN 2 ) minus (Units of outcomeA 1 *$value per unit of outcomeA 1 )+(Units of outcomeB 1 *$value of outcomeB 1 )+ (Units of outcomeN 1 *$value per unit of outcomeN 1 )] Outcomes are converted first to QALYs, Quality Adjusted Life Years (1 year of life at full health minus discount for reduced quality), then to $, e.g., if one year of full health is worth $200,000, and having one ADL dependency reduces the value of life by 20%, then prevention of loss of independence in one ADL=$40,000

Weissert 14 Value of Life Usually estimated by either human capital approach (lifetime earnings) but produces discrimination problems, or preferably willingness to pay (also called contingent valuation) – as revealed by extra pay for extra risky jobs, or population cost of life- saving products like air bags divided by lives saved in the population

Cost-Benefit Example 17Weissert

16 Discounting If costs and benefits flow over a different time, then discounting should be applied Often ignored on the assumption that most benefits are short term –Not a bad assumption in long-term care –Worse assumption for early prevention Requires applying a discount rate for each year of delay between costs and outcomes, –e.g. value of outcomes to come in 5 years might be discounted at 3%/year*5years –Or, if some costs or benefits are short term, and others long, apply discounting to both long term values

Weissert 17 An Application of Cost-Benefit Analysis to Home Care Budgeting

Problems with Home Care Not cost-minimizing –Utilization and cost results poor –Minimally reduced hospital use –Some nursing home reduction »But not enough to offset new costs –Net costs 15-20% higher Not cost-effective –Few outcome benefits, very high cost per benefit – No physical or mental benefits –ADL, IADL, activities, other measures – No increase in longevity – Contentment higher (though transient) in: »some patients »some family care-givers Weissert20

Weissert 19 Underlying Cause: Imperfect Agency Perfect agent requires: –Clear goals from principal –Good information Tools, procedures, resources, training, feedback –Appropriate incentives Rewards, constraints, sanctions

Observed Versus Predicted: Mean Rate of Hospitalization for Selected Subgroups  CharacteristicPredicted ActualRatio  Male  Age over  Human help toileting  Human help transfer  Human help eating  Human help w/mobil  Mental/Alz. dx  Respiratory dx  Nonhyperten. circ.dx Weissert32

Weissert 21 Resource allocation is random Figure 1. Per Capita Spending by Decile of Hospitalization Risk in ALTCS ’92-97

Weissert 22 Figure 2. Per Capita Spending by Decile of Nursing Home Admission Risk in ALTCS ’92-97

Weissert 23 Figure 3. Per Capita Spending by Decile of Risk of Death in ALTCS ’92-97

Weissert 24 Figure 4. Per Capita Spending by Decile of Functional Decline Risk in ALTCS ’92-97

Weissert 25 Reform Agenda: Improve Agency Clarify goals –Focus on patient specific outcome goals Improve information Provide risk assessment tools –Reduce false positives in selection Replace single, categorical eligibility with multistage process –Create demand for dose-response data Create incentives for efficiency, effectiveness –Impose budget constraint binding on every patient –Focus care planning on marginal benefit for marginal cost

Weissert 26 Effectiveness, Risk, Value (ERV) Budget Model Clarifies goals –Emphasizes patient-specific outcomes Accommodates broad range of outcomes Improves information –Provides better risk assessment methods –Employs two-stage needs assessment –Implies care plan evaluation criteria Creates incentives for marginal benefit- marginal cost trade-offs –Sets binding constraint on care plan costs –Shifts funds from low risk to high risk patients –Rewards improved effectiveness

Weissert 27 ERV Example for One Risk If… –Hospital risk for a given patient = 25%, and, –Cost of hospitalization would be = $10,000, and –Effectiveness of home care in mitigating hospital risk = 20%, –Then, monthly ERV= $500 »(500=.20*.25*10,000) Note incentives: – Higher effectiveness=more money –Spending reallocated to highest risk-benefit potential –Process, outcome evaluation criteria implied

Weissert 28 Some Case Examples

Weissert 29 Take-Away Points About Cost- Effectiveness Analysis Central purpose of CEA: –Compare relative value of marginal costs of new policy to marginal value of health benefits produced Specify all current costs and new costs For a single outcome, subtract old costs from new, and Subtract old benefit levels from new –Divide net cost by number of clients benefiting For multiple outcomes, convert all outcomes to QALYs QALYs must be valued to produce value of benefits CEA doesn’t render decisions, only input –Just trying it will improve your decision process Makes you clear about what you’re likely to get and costs –May help you think about what’s feasible and what’s not